Thermo Fisher Scientific (TMO) Cash from Financing Activities (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Cash from Financing Activities for 18 consecutive years, with -$1.6 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Financing Activities fell 58.53% year-over-year to -$1.6 billion; the trailing twelve-month figure through Jun 2026 stood at $2.4 billion (up 140.61% YoY), and the FY2025 full-year result was $1.8 billion, up 126.52% from the prior year.
• Cash from Financing Activities slipped to -$1.6 billion in Q2 2026 per TMO's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $3.5 billion in Q4 2025 and bottomed at -$3.7 billion in Q4 2024.
• Historically, Cash from Financing Activities has averaged -$661.2 million across 5 years, with a median of -$1.1 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities slumped 2406.58% in 2022, then surged 1328.48% in 2023.
• Over 5 years, Cash from Financing Activities stood at $2.4 billion in 2022, then tumbled by 159.72% to -$1.4 billion in 2023, then slumped by 156.72% to -$3.7 billion in 2024, then surged by 196.18% to $3.5 billion in 2025, then tumbled by 144.55% to -$1.6 billion in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$1.6 billion, $1.1 billion, and $3.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.